Physician profile
William E Weiner
NPI 1598782443
$2,074.95
in general payments reported to CMS, 2019-2025
30 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $803 · 2020: $63.08 · 2021: $14.58 · 2022: $162 · 2023: $541 · 2024: $367 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $284.39 | 2019-2025 | Iclusig |
| Abbvie INC. | $249.62 | 2022-2024 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $224.85 | 2019-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $166.37 | 2019-2023 | |
| Myriad Women'S Health, INC. | $134.09 | 2023 | Myrisk |
| Astellas Pharma US INC | $96.51 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.06 | 2019-2024 | Jardiance |
| Exact Sciences Corporation | $90.76 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $79.41 | 2019-2024 | Shingrix |
| Phathom Pharmaceuticals, INC. | $77.74 | 2023-2024 | Voquezna |
| Medtronic, INC. | $67.96 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $60.59 | 2023-2024 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $50.24 | 2022-2023 | |
| Lilly USA, LLC | $41.65 | 2019-2024 | Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $37.75 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $37.42 | 2019-2021 | |
| Amgen INC. | $32.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $30.02 | 2019-2022 | |
| Indivior INC. | $28.56 | 2024 | Sublocade |
| Mallinckrodt Enterprises LLC | $27.72 | 2019 | |
| Axsome Therapeutics, INC. | $26.19 | 2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $21.20 | 2019 | |
| Amarin Pharma, INC. | $16.20 | 2020 | |
| Halozyme INC | $16.05 | 2023 | |
| Mylan Specialty L.P. | $15.68 | 2019 | |
| Shire North American Group INC | $15.09 | 2019 | |
| Allergan, INC. | $14.68 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.30 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.47 | 2019 | Xyosted |
| E.R. Squibb & Sons, L.L.C. | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Weiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.